Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer

TADAHIRO SHOJI, ERIKO TAKATORI, SHINYA HATAYAMA, HIDEO OMI, MASAHIRO KAGABU, TATSUYA HONDA, SEISUKE KUMAGAI, YUICHI MOROHARA, FUMIHARU MIURA, AKIRA YOSHIZAKI and TORU SUGIYAMA

Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka 020-8505, Japan

Received January 7, 2010; Accepted March 17, 2010

DOI: 10.3892/ol_00000091

Abstract. The present study aimed to assess the antitumor response and safety of a tri-weekly neoadjuvant chemotherapy regimen consisting of cisplatin and irinotecan for the treatment of locally advanced cervical cancer with a bulky mass. Between June 2002 and March 2008, 20 patients with locally advanced squamous cell carcinoma of the uterine cervix at clinical stage Ib2-IIIb were studied. Two 21-day cycles consisting of intravenous administration of cisplatin at 70 mg/m² (Day 1) and irinotecan at 70 mg/m² (Days 1 and 8) were performed. Antitumor responses, adverse events and the surgery completion rate were investigated. The response rate of the 15 stage I-II patients was 86.7%, while that of the 5 stage III patients was 20%. Grade 3 or 4 neutropenia was noted in 12 patients, and 4 patients had grade 3 or 4 anemia. Queasiness and vomiting, as grade 3 or 4 non-hematotoxic events, occurred in 1 patient, but none of the patients had diarrhea. The surgery completion rate was 75%. The present data indicate that the tri-weekly cisplatin and irinotecan combination neoadjuvant chemotherapy involves only controllable toxicity and yields a high response rate, suggesting that this combination is a useful therapy regimen.

Introduction

Therapy in Japan for stage Ib2-IIb cancer of the uterine cervix with a bulky mass differs from that in Europe and the US. Based on the results of numerous large-scale randomized clinical studies and meta-analyses of the data, concurrent chemoradiation (CCRT) is recommended as a standard therapy in Europe and the US (1-7). An approach to neoadjuvant chemotherapy (NAC) was introduced in Japan, as well as in other countries, such as Korea and Italy (8). The clinical significance of NAC involves: i) contraction of the tumor size in an attempt to improve permanent curability and safety of surgery, and ii) an anticipated systemic effect on latent/micro-lymph node metastasis. However, this approach has the disadvantage of causing a delay in the initiation of the primary treatment. Thus, it is necessary to complete NAC as an adjunctive therapy in a short period of time.

Irinotecan hydrochloride, an inhibitor of DNA topoisomerase I, has received considerable attention as an anticancer drug, which, in the active metabolite form, exerts an antitumor effect by inhibiting nucleic acid synthesis. Irinotecan administered alone or in combination with cisplatin is useful in the treatment of recurrent cervical cancer (9,10). Cisplatin and irinotecan chemotherapy with a schedule consisting of cisplatin administered on Day 1 and irinotecan on Days 1, 8 and 15, followed by a 2-week withdrawal, is recommended as a standard regimen (11). The present study was conducted to assess the toxicity and efficacy of a tri-weekly cisplatin and irinotecan combination chemotherapy regimen with an increased cisplatin dose intensity and concurrent irinotecan, in order to reduce the duration of the therapy regimen to the primary surgical treatment.

Patients and methods

Patients. The study population comprised 20 patients with locally advanced squamous cell carcinoma of the uterine cervix at FIGO stage Ib2-IIb, who were scheduled for radical hysterectomy. The patients gave informed consent. The study was conducted June 2002 and March 2008.

Inclusion criteria. Inclusion criteria for the study included: i) histologically verified squamous cell carcinoma of the uterine cervix; ii) locally advanced stage Ib2-IIb disease; iii) ≥20 years and <70 years of age (or <45 years in the case of patients with stage III disease who selected conservation of the ovary); iv) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; v) initially treated case; vi) presence of a magnetic resonance imaging (MRI)-measurable bulky mass in the uterine cervix; vii) hematological and blood biochemical findings meeting the following criteria: WBC count ≥4,000/mm³, neutrophil count ≥2,000/mm³, platelet

Correspondence to: Dr Tadahiro Shoji, Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka 020-8505, Japan
E-mail: tshoji@iwate-med.ac.jp

Key words: cervical cancer, cisplatin, irinotecan, neoadjuvant chemotherapy
Exclusion criteria. Exclusion criteria included: i) patients with overt infection; ii) patients with a serious complication(s) (e.g., cardiac disease, poorly controlled diabetes mellitus, malignant hypertension and bleeding tendency); iii) patients with active multiple cancer; iv) patients with interstitial pneumonia or pulmonary fibrosis; v) patients with effusions; vi) patients with a history of unstable angina or myocardial infarction within 6 months after registration, or with a concurrent serious arrhythmia requiring treatment; vii) patients for whom treatment with cisplatin and irinotecan is contraindicated; viii) patients with (watery) diarrhea; ix) patients with intestinal paralysis or ileus; x) pregnant women, nursing mothers or women wishing to become pregnant; xi) patients with a history of serious drug hypersensitivity or allergy; and xii) patients who were inadequate for safe conduct of this study as judged by the attending physician.

**Exclusion criteria.**

- Patients with overt infection
- Patients with a serious complication(s) (e.g., cardiac disease, poorly controlled diabetes mellitus, malignant hypertension and bleeding tendency)
- Patients with active multiple cancer
- Patients with interstitial pneumonia or pulmonary fibrosis
- Patients with effusions
- Patients with a history of unstable angina or myocardial infarction within 6 months after registration, or with a concurrent serious arrhythmia requiring treatment
- Patients for whom treatment with cisplatin and irinotecan is contraindicated
- Patients with (watery) diarrhea
- Patients with intestinal paralysis or ileus
- Pregnant women, nursing mothers or women wishing to become pregnant
- Patients with a history of serious drug hypersensitivity or allergy
- Patients who were inadequate for safe conduct of this study as judged by the attending physician

**Treatment protocol.** We designed the treatment schedule on the basis of a phase II clinical study in patients with small-cell lung carcinoma. Two 21-day cycles consisting of intravenous administration of cisplatin (CDDP) at 70 mg/m² on Day 1 and irinotecan (CPT-11) at 70 mg/m² on Days 1 and 8 were performed (Fig. 1).

**Criteria for the initiation of the second cycle**

Initiation of the second cycle was postponed up to a maximum of 2 weeks when the hematologic test values within 2 days before the scheduled second cycle initiation failed to fulfill the following criteria: a) neutrophil count ≥1,500/mm³ and b) platelet count ≥75,000/mm³.

**Criteria for CPT-11 dose skip.** The irinotecan dose on Day 8 was skipped when hematological test values within 2 days before Day 8 failed to fulfill the following criteria: a) neutrophil count ≥1,000/mm³ and b) platelet count ≥75,000/mm³.

**Dose modification criteria**

**Criteria for the initiation of the second cycle.** Initiation of the second cycle was postponed up to a maximum of 2 weeks when the hematologic test values within 2 days before the scheduled second cycle initiation failed to fulfill the following criteria: a) neutrophil count ≥1,500/mm³ and b) platelet count ≥75,000/mm³ and c) serum creatinine ≤1.5 mg/dl.

**Dose reduction criteria.** The doses of cisplatin and irinotecan were reduced to 70 and 60 mg/m², respectively, in the second course for patients who presented any of the following signs of toxicity in the first cycle: i) grade 4 neutropenia persisting for ≥7 days, ii) febrile neutropenia persisting for ≥4 days, iii) grade 4 thrombocytopenia, iv) grade 3 thrombocytopenia with hemorrhage and v) grade ≥3 non-hematologic toxicity excluding nausea, vomiting, appetite loss, fatigue and hair loss.

**Supportive therapy.** Therapeutic administration of G-CSF preparations was undertaken in the case where grade 4 neutropenia was noted in the first cycle. In the second and subsequent cycles, prophylactic use of the preparation in patients with grade 3 neutropenia was acceptable when grade 4 neutropenia was noted in the first cycle. Antiemetics were used for preventive purposes.

**Endpoints/variables.** The primary endpoint was an antitumor response and the secondary endpoints comprised adverse events and surgery completion rate. The antitumor response and surgery completion rate were calculated for the subgroups of FIGO stage I-II and III. As a rule, hematological tests and urinalysis were performed prior to the subjected chemotherapy and at weekly intervals after chemotherapy commenced. Electrocardiography and a chest X-ray examination were conducted prior to commencing and at completion of the chemotherapy.

**Evaluation of antitumor response.** Pre-treatment MRI was regarded as baseline data. MRIs were therefore obtained at completion of the first and second cycles, and the antitumor response was rated according to the Response Evaluation Criteria in Solid Tumors. Assessments of the duration of response were not taken into account in this evaluation.

**Method of assessing adverse events.** The National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) version 3.0 was used to assess adverse events.

**Figure 1.** Treatment protocol of the neoadjuvant chemotherapy.

**Table I.** Patient characteristics (n=20).

<table>
<thead>
<tr>
<th>FIGO stage at initial diagnosis</th>
<th>Stage I-II</th>
<th>Stage III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ib</td>
<td>3 (15%)</td>
<td>2 (10%)</td>
</tr>
<tr>
<td>IIA</td>
<td>10 (50%)</td>
<td>5 (25%)</td>
</tr>
<tr>
<td>IIB</td>
<td>10 (50%)</td>
<td></td>
</tr>
<tr>
<td>IIIb</td>
<td>5 (25%)</td>
<td></td>
</tr>
</tbody>
</table>

**Tumor diameter:**

- <5 cm: 10 (50%)
- ≥5 cm: 10 (50%)

*Measured by MRI, magnetic resonance imaging.*
down-stage progression. CCRT was carried out on patients whose conditions were inoperable.

**Postoperative therapy.** Postoperative radio- or chemotherapy was undertaken in patients with positive vaginal stump, positive lymphadenopathy, positive invasion of the cardinal ligament or evident invasion of the vasculature.

### Results

**Demographic and baseline clinical characteristics.** Regarding the age distribution of the 20 enrolled patients, stage I-II patients ranged from 25 to 56 years of age (median 40) and stage III patients from 40 to 44 years of age (median 44). The PS was 0 in 17 patients (85%) and 1 in 3 patients (15%). The FIGO stage at initial diagnosis was stage Ib2 in 3 patients (15.8%), stage IIa in 2 (10.5%), stage IIb in 9 (47.4%) and stage IIIb in 5 patients (26.3%) (Table I).

**Antitumor response.** Of the 15 stage I-II patients, the antitumor response was complete response (CR) in 4 patients (26.7%), partial response (PR) in 9 (60%), stable disease (SD) in 1 (6.7%) and PD in 1 patient (6.7%). Of the 5 stage III patients, the response was PR in 1 patient (20%) and SD in 4 patients (80%). The overall response rates of stage I-II and III patients were 86.7 and 20%, respectively (Table II).

**Toxicity and treatment received.** Grade 3 and 4 neutropenia was noted in 6 patients (30%) each, while 2 patients (10%) experienced febrile neutropenia. G-CSF preparations were administered to 11 (55%) of the 20 patients during 17 (42.5%) of a total of 40 cycles. The mean duration of the use of G-CSF preparations was 3.4 days per cycle. Three patients (15%) had grade ≥3 anemia, and 1 patient with grade 4 anemia received a blood transfusion. No patients developed grade ≥2 thrombocytopenia. Nausea and vomiting, as grade ≥3 non-hematotoxic events, occurred in 1 patient (5%) each, and both patients were administered parenteral fluid infusions (Table III). Chemotherapy was completed as scheduled by 18 (90%) of the 20 patients. The irinotecan dose on Day 8 in the second cycle was skipped in the remaining 2 patients. These skips were made due to persistent nausea, based on the judgment of the attending physician. Although the second cycle was started within 7 days of the first in 3 patients, this second cycle of postoperative chemotherapy was postponed in all 3 (15%) patients due to failure of the neutrophil count to adhere to the initiation criterion. The cisplatin and irinotecan dose was reduced in the second cycle in 2 patients (10%) with febrile neutropenia lasting for ≥4 days.

### Surgery completion rate.

Of the total of 20 patients, 18 (90%) underwent surgery for the disease. A radical hysterectomy was completed in 15 of these patients; thus, the overall surgery completion rate was 75%. For the 15 stage I-II patients, the radical hysterectomy completion rate was 93.3%, since the surgical operation was incomplete in a patient with PD. Surgery was performed in three stage III patients, with a radical hysterectomy being completed in 1 patient with PR; thus, the completion rate was 33.3%.

### Discussion

The key drug for the treatment of advanced/recurrent cervical cancer is cisplatin (50 mg/m²); thus, a variety of combination therapy regimens with cisplatin were investigated (12-14). Results of randomized studies by the Gynecologic Oncology Group (GOG) demonstrated the usefulness of cisplatin in combination with paclitaxel or topotecan, and the use of cisplatin along with another antineoplastic agent was recommended for the treatment of advanced/recurrent cervical cancer (13,14). At the 2008 Annual Conference of the American

---

**Table II. Antitumor response.**

<table>
<thead>
<tr>
<th>FIGO stage</th>
<th>CR (%)</th>
<th>PR (%)</th>
<th>SD (%)</th>
<th>PD (%)</th>
<th>Overall response rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-II (n=15)</td>
<td>3 (20.0)</td>
<td>10 (66.7)</td>
<td>1 (6.7)</td>
<td>1 (6.7)</td>
<td>13 (86.7)</td>
</tr>
<tr>
<td>III (n=5)</td>
<td>0 (0.0)</td>
<td>1 (20.0)</td>
<td>4 (80.0)</td>
<td>0 (0.0)</td>
<td>1 (20.0)</td>
</tr>
</tbody>
</table>

**Tumor diameter**

| <5 cm (n=10) | 4 (40.0) | 4 (40.0) | 1 (10.0) | 1 (10.0) | 8 (80.0) |
| ≥5 cm (n=10) | 0 (0.0) | 6 (60.0) | 4 (40.0) | 0 (0.0) | 6 (60.0) |

**CR, complete response; PR, partial response; SD, stable disease and PD, progressive disease.**

**Table III. Toxicity.**

<table>
<thead>
<tr>
<th>Grade</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>≥3 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukopenia</td>
<td>4</td>
<td>9</td>
<td>5</td>
<td>2</td>
<td>7 (35)</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>1</td>
<td>7</td>
<td>6</td>
<td>6</td>
<td>12 (60)</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Anemia</td>
<td>5</td>
<td>11</td>
<td>3</td>
<td>1</td>
<td>4 (20)</td>
</tr>
<tr>
<td>Nausea</td>
<td>14</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>12</td>
<td>7</td>
<td>1</td>
<td>0</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Neurotoxicity</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Renal toxicity</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>2 (10)</td>
</tr>
</tbody>
</table>
of irinotecan was skipped by 2 patients. The dose was reduced in patients with a tumor size ≥5 cm (Table II). The results were consistent with reports that the smaller the size of the tumor was, the lower the response rate according to tumor size (diameter) was 80% for patients who received combination chemotherapy with doses administered at 4-week intervals, irinotecan doses on Days 8 and 15 were skipped in approximately 30% of patients. However, the efficacy of the therapies was confirmed even in patients with dose skips, suggesting the need for reassessment of the appropriate method for the dosing of cisplatin and irinotecan chemotherapy.

On the other hand, a meta-analysis of data concerning NAC yielded results that negated the efficacy of treatment with radiation therapy as a primary regimen. Results of the meta-analysis, nevertheless, suggested that NAC is useful as treatment when i) each cycle extends to 14 days or less, and ii) the cisplatin dose intensity is ≥25 mg/m²/week (16). Consequently, the present study examined the efficacy and safety of cisplatin and irinotecan chemotherapy, documented to be efficacious as NAC, with modifications of the dose and dosing schedule. Doses of cisplatin and irinotecan were set at 70 mg/m²; the former was administered on Day 1 of each cycle and the latter on Days 1 and 8, and each patient received 2 tri-weekly cycles of the regimens. Thus, the dose intensity of cisplatin was increased to 23.3 mg/m²/week, leading to a decrease in the dose skip rate according to this dosing schedule. In turn, 2-week reduction in duration to surgery occurred.

The overall response rate was 70% in the study regimen, while the response rate for stage I-II patients was 86.7%, which appeared to be comparable to or even greater than the monthly regimen. In contrast, of the 5 stage III patients requiring conservation of ovarian function, NAC proved effective only in 1 patient, enabling a radical hysterectomy, and indicating the difficulty of NAC in stage III cases. The response rate according to tumor size (diameter) was 80% for the 10 patients with a tumor size <5 cm and 60% for the 10 patients with a tumor size ≥5 cm (Table II). The results were consistent with reports that the smaller the size of the tumor mass, the greater the efficacy of NAC (17,18). Our findings suggest that a tumor size ≥5 cm may constitute a risk factor for NAC as described by Huang and co-researchers (19).

Regarding adverse events, a high incidence of neutropenia was noted, which decreased in response to brief G-CSF treatment (mean duration 3.4 days). Severe diarrhea characteristic of irinotecan chemotherapy did not occur at the dose level of 70 mg/m²; thus, quality of life appeared to be maintained. Patients completed the first cycle as scheduled, whereas in the second cycle, the initiation of the treatment was postponed within a period of 1 week for 3 patients, and the Day 8 dose of irinotecan was skipped by 2 patients. The dose was reduced during the second cycle for only 2 patients; thus, the present regimen was considered to confer no increased toxicity as compared to the monthly regimen.

In conclusion, the present study demonstrated that the tri-weekly cisplatin and irinotecan combination chemotherapy with an increased dose intensity of cisplatin at 70 mg/m² was safely conducted, yielded a high response rate and proved useful as a NAC regimen.

References


